Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Intrathecal Pemetrexed for Leptomeningeal Metastasis After High-Dose Third-Generation EGFR TKI Failure
ChiCTR2400081621Phase 2Not yet recruiting
- Sponsor
- Third People's Hospital of Huizhou
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in Carcinomatous Meningitis (CM) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Third People's Hospital of Huizhou. Primary endpoints: Clinical response rate and Neurological progression-free survival (NPFS). Planned start Mar 2024; status: not yet recruiting.
02
Drugs
pemetrexed
03
Conditions
Carcinomatous Meningitis (CM)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400081621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081621.